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Abstract: In gastric cancer (GC), epidermal growth factor receptor (EGFR) overexpression associates with poor 
prognosis. Addition of a chimeric monoclonal antibody against EGFR (cetuximab) to first-line treatment of 
metastatic colorectal tumours improved outcomes of patients (stratified for KRAS wild-type cancers), whereas 
GC patients did not benefit from this approach. In GC, however, stratification based on KRAS mutations was 
not performed, and the 30% KRAS mutation frequency in Microsatellite instable cancers (MSI), which represents 
~4% of total GC was disregarded. Further, intratumoural heterogeneity regarding KRAS mutant subpopulations 
might also contribute to anti-EGFR therapy failure. We assessed the mutational status of the KRAS entire coding 
sequence in 19 MSI-GC cases by multiplex PCR/Sequencing, and used peak height ratio determined from 
electropherograms from KRAS heterozygous mutants and histopathological evaluation to infer tumour 
heterogeneity in GC. Using 2 multiplex reactions per sample we found that 26% (5/19) of MSI-GC cases 
harboured KRAS mutations (2 G12D, 2 G13D, 1 G12V). No mutations were found outside the codon 12 and 13 
hotspots. Our analysis supported the co-existence of KRAS-positive and -negative tumour populations in 4/5 
MSI-GC cases. In conclusion, the method developed stands as a cost-effective and practical way for mutation 
screening of the entire KRAS coding sequence. KRAS mutations are frequent in our series of MSI cases, and 
are often found in a subpopulation of the tumour and not in the whole tumour. Further studies are needed to 
access the implications of this heterogeneity in KRAS mutant and wild-type tumour clones in anti-EGFR therapy 
response. 
 
Keywords (4-6): KRAS, microsatellite instability, MSI, gastric cancer, gastric cancer treatment  
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Introduction 
 
In 2012, gastric cancer’s (GC) incidence was reported to be of 952,000 cases (representing 6.8% of 
total), with a mortality of 723,000 patients (8.8% of total) worldwide. Even though over 70% of cases occur in 
developing countries, it ranks sixth in developed countries’ numbers of both incidence and mortality [1]. Both 
incidence and mortality have been declining appreciably over the last decades, but they remain high mainly due 
to advanced stage of disease at presentation, lack of understanding of the complex biology, and morphologic 
and molecular heterogeneity. 
The progress in GC therapy has been limited. Currently, surgery is the only method capable of curing 
patients and remains the first choice for early-stage disease, although endoscopic resection is being 
increasingly used in selected early-stage tumours [2]. Adjuvant chemo and radiotherapy may result in improved 
survival for some of these early-stage patients, but neither the methods nor the outcomes of this approach have 
been consensual in previous reports [2]. As for advanced-stage GC, chemotherapy should be considered for 
all patients, given its proven benefits in survival and quality of life, with patients with HER2+ tumours also 
meriting targeted therapy such as trastuzumab [3]. However, the prognosis remains very poor for patients with 
GC, with 5-year survival rates of only 30% in Western countries [3]. Thus, the need to better comprehend the 
molecular behaviour of the disease is urgent, and the current paradigm begets the need of a more appropriate 
and individualized therapy [2,4]. 
It has been accepted for many years that there are at least two mutually exclusive molecular types of 
GC: the chromosomal instability (CIN) type, characterized by structural alterations, namely large deletions, 
amplifications and translocations; and the microsatellite instability (MSI) type, with instability at the nucleotide 
level. The MSI type is characterized by alterations in the length of nucleotide repeat sequences, and marks an 
underlying mismatch repair (MMR) deficiency, meaning that cells fail to recognize errors introduced during DNA 
replication, which are prone to occur at those nucleotide repeat sequences (microsatellites) [5]. 
MSI is observed in approximately 15-20% of sporadic GC and also in sporadic colorectal cancer (CRC) 
with a similar frequency, appearing to be associated with a more favourable prognosis in both cancer types 
[6,7]. MSI tumours from both colon and stomach are associated with specific profiles of target gene mutations 
that include insertions/deletions at microsatellite stretches in coding and noncoding sequences, but also with 
hotspot missense mutations at the KRAS (stomach and colon) and BRAF genes (colon) [8,6,9]. KRAS, a 
molecule of the MAP kinase (MAPK) pathway and a target gene of the MSI molecular phenotype, was reported 
to have no difference in mutation frequency between MSI and non-MSI (i.e. microsatellite stable (MSS)) CRC 
cases [10], or to have lower frequency in MSI as compared with MSS tumours [11,9,12]. Interestingly, in GC, 
KRAS mutations are generally restricted to the MSI group of cancers, and have been described in nearly 30% 
of these cases using specific analysis of KRAS exon 2, affecting the hotspot codons 12 and 13 of the gene  
[9,13]. Aside from these exon 2 hotspots, KRAS mutation frequency seems to be lacklustre. Although in GC, 
the information on KRAS mutations outside these hotspots is scarce, 6.5% of a CRC series of 276 cases 
demonstrated KRAS mutations in other codons of the gene [14]. 
 In CRC, the addition of cetuximab (a chimeric monoclonal antibody against the epidermal growth factor 
receptor (EGFR)) to irinotecan, fluorouracil, and leucovorin, as first-line treatment for metastatic tumours, was 
shown to reduce the risk of disease progression, and to increase the chance of response in patients with KRAS 
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wild-type (WT) disease [15]. EGFR positivity, determined by immunohistochemistry, is however regarded as a 
non-relevant predictive marker of response to this targeted therapy [16]. Indeed, anti-EGFR therapy is reserved 
for RAS WT tumours, since CRC bearing mutations of either KRAS or NRAS are irresponsive to this treatment 
[16]. These are gain-of-function mutations that activate the EGFR signalling pathway at a downstream location, 
rendering the antibodies against this molecule useless [17]. Since this targeted therapy is currently used in CRC 
patients, predictive testing for RAS mutational status is needed, generally using a tumour biopsy sample [17]. 
However, these specimens are often single, and thus represent only a small region of the tumour, limiting the 
possibility of detecting positive RAS-clones at different sites of the tumour [17]; nonetheless, RAS mutational 
screening is definitive to guide anti-EGFR treatment in CRC patients [16]. 
In GC, EGFR overexpression occurs and is associated with poor prognosis [18]; this finding, together 
with the observed improved outcomes regarding anti-EGFR therapy in KRAS WT metastatic CRC [15], recurrent 
or metastatic squamous-cell cancer of the head and neck and advanced non-small-cell lung carcinoma, 
supported the rationale to perform the EXPAND trial in GC [19]. Cetuximab was added to first-line chemotherapy 
treatment in advanced non-resectable or metastatic GC, but failed to produce improved outcomes. Also, a 
subpopulation analysis in this trial revealed no association between EGFR positivity (determined by 
immunohistochemistry) and overall survival in patients treated either with or without cetuximab, suggesting a 
non-predictive role for EGFR positivity in GC regarding anti-EGFR therapy, similarly to what occurs in CRC. 
However, the EXPAND trial failed to account for the presence of KRAS mutations in at least 4-10% of GC overall 
[9,13,20]. Taking in consideration the KRAS mutation-mediated anti-EGFR resistance in CRC, this fact could 
explain, to a certain extent, the failure of the EXPAND trial. Therefore, in case anti-EGFR therapy trials are 
reconsidered in GC, it would be important to use MSI-positivity (which represents roughly 15-20% of all cases), 
and its accompanying frequency of KRAS mutation in hotspot codons 12 and 13, as part of the GC treatment 
stratification plan. Also, if a more thorough stratification is to be performed, rigorously checking for mutations, 
both inside and outside the KRAS hotspot regions of the gene, could also prove worthy. 
 Another important issue in therapy response is intratumoural molecular heterogeneity, a feature of 
malignant neoplasias that experienced competition between different tumour cells (or clones) for survival, 
leading to the evolutionary selection of different cell kindred and their progeny [21-23]. A study on metastatic 
CRC, using a highly sensitive picodroplet digital PCR (dPCR), found that some KRAS WT cases actually 
harboured KRAS mutations. Moreover, the fraction of KRAS-mutated allele, quantified by dPCR, was inversely 
correlated with anti-EGFR therapy response rate [24]. These authors hypothesised that while the majority of 
KRAS WT tumour cells in these cases would respond to anti-EGFR therapy, tumour subclones bearing KRAS 
mutations would not. These observations could explain why nearly 50% of CRC cases considered KRAS WT, 
and regarded as responders to anti-EGFR therapy, do not benefit from this approach [24]. This same fact might 
also contribute to explain the failure of the addition of anti-EGFR therapy to first-line chemotherapy in producing 
improved outcomes in GC. 
 With this work, we aim to assess the mutational status of the entire coding sequence of KRAS in MSI 
GC cases, and use peak height ratio determined from electropherograms from KRAS heterozygous mutants 
and histopathological evaluation to infer the tumour heterogeneity in GC cases. To achieve these aims, we 
developed a multiplex PCR reaction for practical and cost-effective mutation screening of the whole KRAS 
coding sequence; we determined the frequency and type of KRAS coding sequence mutations in a series of 19 
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MSI-positive GC cases; and we inferred tumour heterogeneity in mutated cases by comparing KRAS WT and 
mutated allelic fractions, as determined by electropherogram analysis, with the percentage of tumour cells in 
matched histological slides. 
 
Materials and Methods 
 
DNA Samples and Extraction 
DNA from AGS, IPA220 and MKN28 gastric cancer cell lines was used for optimization of the multiplex 
PCR. The DNA was extracted from in vitro cultured cells using Spin Tissue Mini Kit (Invisiorb®) according to 
manufacturer’s instructions. DNA quantification and purity were determined using a spectrophotometer 
(Nanodrop®), and aliquots were created by diluting the DNA of each cell line as to create a working solution of 
50ng/µl. 
Primary gastric cancer DNA samples were obtained from 19 cases of the Tumour Bank from Centro 
Hospitalar São João and IPATIMUP. Informed consent was obtained from all patients, and the study was 
approved by the Hospital's Ethics Committee. These tumour samples had been previously characterized for the 
presence of MSI phenotype using Pentaplex Kit (Roche®). The DNA content of each sample was determined 
using the method described above, and aliquots were created in the same manner.  
 
Polymerase Chain Reaction & Primers 
Primers were designed in intronic regions flanking KRAS exons, and were produced by SIGMA® (Table 
1). Working solutions for each primer at a concentration of 100 µM were created. QIAGEN® Multiplex PCR Kit 
was used according to the manufacturer’s instructions. Briefly, the Polymerase Chain Reaction (PCR) was 
conducted using the following ingredients for each sample: 12.5 µl of QIAGEN® Multiplex Master Mix, 1 µl of 
primer mix (composed of reverse and forward primers for the corresponding exons in equal proportions), 5 µl 
of QIAGEN® Q-solution, 1 µl of DNA at working solution and 5.5 µl of DNAse and RNAse-free water. The 
following cycling conditions were used for PCR: 15 min of 95 ºC for enzyme activation, followed by 30 sec at 94 
ºC, 90 sec at 62 ºC and 90 sec at 72 ºC for 3 cycles, 30 sec at 95 ºC, 90 sec at 60 ºC and 90 sec at 72 ºC for 3 
cycles, 30 sec at 95 ºC, 90 sec at 58 ºC and 90 sec at 72 ºC for 24 cycles and an extension phase of 72 ºC for 
the final 10 min. 
 
Sequencing Reaction 
After the multiplex PCR, product clean-up was achieved by mixing 10 µl of each multiplex product with 
1 µl of Exonuclease I (ExoI) and 2 µl of Thermosensitive Alkaline Phosphatase (FastAP™), and exposing the 
solution to 37 ºC for 15 min and 85 ºC for 15 min. This was performed separately for each sample. Each exon 
was sequenced independently by using the corresponding primer (shown in bold in Table 1). For each 
sequencing reaction 2 µl of cleaned-up DNA were mixed with 0.5 µl of sequencing buffer, 0.4 µl of BigDye® 
terminator (both of Applied Biosystems®), 0.4 µl of primer (at working solution) and 1.7 µl of DNAse and RNAse-
free water. The cycling conditions used for the reaction were the following: 96 ºC for 2 min, followed by 30 cycles 
of 30 sec at 96 ºC, 15 sec at 54 ºC and 150 sec at 60 ºC; the final extension was performed at 60 ºC for 10 min. 
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Post-sequencing purification was performed by cross-link dextran gel filtration. A tube for each exon 
from all the samples was centrifuged at 2000 x g for 4 min with a Sephadex® solution at a concentration of 0.66 
mg/ml. The sequencing product was then purified using 5 µl of it under the same centrifugation conditions. The 
purified product was analysed using an automated sequencer. 
 
Histological & Electropherogram Analysis 
Frozen tumour fragments, deposited at the Tumour Bank from Centro Hospitalar São João and 
IPATIMUP, used for DNA sampling were matched with fragments that were paraffin embedded for 
histopathological analysis. Haematoxylin and eosin (H&E) stained slides from KRAS mutant GC cases were 
examined by a pathologist from the Department of Pathology of Centro Hospitalar São João (Fátima Carneiro), 
who determined the approximate percentage of tumour cells present in each slide. The minimal percentage of 
tumour cells in each case was registered. Then, the (lowest) expected mutant-to-WT allelic ratio was 
determined, that is, the ratio when considering that the whole tumour cell population is mutated for KRAS, and 
that all tumour cells are heterozygous for the mutation (meaning that each cell bears one WT and one mutated 
allele). The following formula was used (in percentage):  
𝑃
2⁄
𝑃
2⁄ + (100 − 𝑃)
× 100 
Where 𝑃 represents the approximate percentage of tumour cells in the slide. With the assumptions 
made above, 𝑃 2⁄  should represent both the mutated and WT allelic fraction of the tumour cell population, while 
(100 − 𝑃) should represent the WT allelic fraction of non-tumoural cells in the slide. 
For each sample submitted to the automated sequencer, an electropherogram was obtained. Peaks on 
the electropherogram were manually analysed for alterations in the WT sequence of each exon, and altered 
cases were classified as mutated. For the mutated cases, the peak height for each nucleotide variant was 
determined using Photoshop® (CC version, Adobe), and the observed mutant-to-WT allelic ratio (in percentage) 
was determined by the following formula: 
(
𝐻1
𝐻2
) × 100 
Where H1 represents the height of the peak for the mutated nucleotide, and H2 represents the height of 
the peak for the WT nucleotide. This followed the strategy described by Jiang et al [25] (Figure 1a). The 
electropherogram from a common KRAS single nucleotide polymorphism (SNP) rs1137282 found in 6/19 GC 
cases studied was used as a control to determine the expected peak height ratio of the nucleotides (representing 
each allele) from a constitutional SNP (Figure 1b). The allelic ratios obtained for this SNP in three different GC 
cases were 89%, 120% and 100%. These were therefore confirmed to represent constitutional heterozygous 
states. 
 
Results 
 
Full coding sequence mutation screening of KRAS with two PCR reactions 
We started by the optimization of a multiplex PCR approach to amplify the full coding sequence of 
KRAS, from exon 2 to exon 6, using three GC cell lines. Following a PCR reaction with 5 primer-pairs, products 
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were confirmed by agarose gel electrophoresis. Sanger sequencing and electropherogram analysis confirmed 
successful concomitant amplification and specificity for exons 2 to 5, but not for exon 6. Exon 6 was therefore 
amplified and sequenced independently (Figure 2).  
The same amplification protocol was then applied to 19 GC tumour samples. Agarose gel 
electrophoresis confirmed the amplification reaction, and sequencing reactions were successful for all cases 
(Supplementary Table 1).  
 
26% of MSI GC cases harbour mutations in the KRAS coding sequence 
Confirming the feasibility of the amplification protocol, we verified that, as expected, the AGS cell line 
presented a KRAS mutation in exon 2 (G12D), while the other two cell lines were WT for all exons. From the 
MSI-positive GC cases studied, 5/19 (26%) were found to be mutated. Two cases carried a G13D mutation, two 
cases carried the G12D mutation and one case carried the G12V mutation. A common SNP (rs1137282) was 
also identified in 7 GC cases (6 in a heterozygous and 1 in a homozygous state), but no mutations were identified 
outside the hotspot region of the gene (Table 2, Supplementary Table 1). 
 
Histological and electropherogram analysis of KRAS mutated cases allow inferring the presence of 
tumour heterogeneity 
The electropherogram analysis from KRAS mutated cases indicated that the peak height corresponding 
to the mutant allele was variable among GC cases (Figure 3). This could have occurred either due to variable 
degrees of stromal contamination in different cases, or due to molecular intratumoural heterogeneity (presence 
of both KRAS mutant and KRAS WT subpopulations in the same GC tumour). To address this issue, we took 
advantage from the fact that the frozen fragment used for DNA extraction had a twin fragment that had been 
paraffin embedded. We therefore re-evaluated the H&E slides of each KRAS mutated case to assess the 
effective percentage of tumour cells in each fragment (Table 3). For each case, the percentage of tumour cells 
was registered for comparison with the allelic ratio observed in the corresponding electropherogram. Figure 3 
shows examples of light microscopy images from the mutated cases and the corresponding electropherogram 
peaks. Comparing the expected mutant-to-WT allelic ratio obtained from the histopathological analysis with the 
peak height ratio determined by electropherogram analysis (observed ratio), 4/5 cases demonstrated an 
“observed ratio” lower than the “expected ratio” (Table 3). Overall, the concordance between observed and 
expected ratios was low, suggesting the existence of heterogeneity in tumour populations in 4/5 cases, where 
some are positive for KRAS mutations and others are negative for these mutations. 
 
Discussion 
 
With this work we intended to develop a multiplex PCR approach that could be used to screen the full 
coding sequence of KRAS using low amounts of DNA  in a cost effective way, and use the sequencing analysis 
in KRAS mutant cases, as well as corresponding histological analysis, to infer molecular heterogeneity related 
with KRAS mutant cancer cell populations. This information may be important if anti-EGFR treatment is re-
evaluated in GC, to allow correct stratification of cases for this type of targeted therapy. 
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Using a multiplex PCR reaction for exons 2 to 5 and an independent PCR reaction for exon 6, mutational 
analysis of the entire coding sequence of the KRAS gene was achieved for all the 19 MSI positive GC cases 
analysed. Reducing the number of PCR reactions needed from a total of 6 (one per exon) to only 2 makes the 
method developed in this study an efficient, yet cost-effective and practical way of amplifying the entire coding 
sequence of this gene. Also, this was achieved using low quantities of DNA. At the moment, this is a relevant 
issue in CRC, as the use of neoadjuvant therapy in these patients is likely to increase in the future. In that case, 
the only tissue available for predictive testing will be the diagnostic biopsy samples, used to confirm the 
presence of the malignant tumour, which may not be present in abundant quantities. Thus, if KRAS testing is to 
be applied in a predictive fashion for neoadjuvant treatment, mutational analysis in limited quantities of DNA 
could be a problem, suggesting the need for strategies that make the most out of the available material, whilst 
not demanding state of the art technology or high budget, like the one designed in this study.  
The frequency of KRAS mutations encountered (approximately 26%) is in accordance with the 
frequency described in previous reports [9,13]. No mutations were found outside the hotspot region of the gene, 
which is also in accordance with some previous studies [20]. Even though in the present study no mutations 
were found outside the hotspots, studies addressing the efficacy of anti-EGFR therapy in GC should not neglect 
the small percentage of cases that might be mutated outside the hotspot region, since they contribute to 
therapeutic failure. In fact, while we were developing this work, the TCGA Consortium reported the whole Exome 
Sequencing analysis of almost 300 GC cases and revealed that in MSI GC cases, the frequency of KRAS 
mutations was of 23%, which matches our own findings [20,26,27]. That study also found that MSS GC cases 
had a KRAS mutation frequency of 6%. One of the premises of the present work was that KRAS mutations were 
restricted to MSI GC cases. The premise of most previous studies was that KRAS mutations only occurred in 
hotspot codons 12 and 13, and therefore only exon 2 was screened [9,13]. The recent discovery of KRAS 
mutations in 6% of MSS GC cases is due to a more thorough search for mutations in the whole gene, 
considering both hotspot and non-hotspot regions, highlighting the pertinence of a strategy for KRAS mutation 
screening, that should now be extended also to MSS GC cases. An additional finding of the TCGA Consortium 
was the amplification of KRAS gene in approximately 7% of GC cases overall [26,27]. In CRC, KRAS 
amplification is also found, although to a much lesser degree (<1%, according to one study) [28], and it has 
been postulated that it might be responsible for resistance to anti-EGFR therapy in some cases.  
Taking in consideration the findings and the experience in CRC, namely regarding the KRAS-related 
resistance to anti-EGFR therapy, it is possible that the failure of this targeted therapy in GC is actually justified 
by the frequency of KRAS alterations. In summary, if anti-EGFR therapy is ever reconsidered in GC, patient 
stratification based on all these mechanisms and disease subsets needs to be considered. 
A perspective that one should not disregard when stratifying patients for treatment is that tumours are 
heterogeneous and most often bear a fraction that will respond to a given targeted treatment, and a fraction that 
will not. If screening strategies are sufficiently sensitive to identify a fraction of the tumour that is likely to 
respond, should these tumours be treated or not? 
In CRC, tumour heterogeneity for KRAS genotype has been well documented [24,29,30] and the 
fraction of mutated cells in the tumours is variable [31]. However, the real impact of this in the behaviour of the 
tumour as a unit is not known, nor are the implications in survival, response to therapy and other outcomes. To 
determine this, studies that include sensitive assays like the one used by Laurent-Puig et al [24] in search of a 
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subpopulation of KRAS mutant clones in KRAS WT cases, the use of these findings for patient stratification 
regarding anti-EGFR therapy, and the evaluation of response to therapy, could shed some light in this matter. 
In the present study, we aimed at determining the relative allelic fraction of KRAS mutant and WT alleles, 
while correlating this value with the fraction of tumour cells in a sample. We have shown that 4/5 of the KRAS 
mutated cases of our series present with both KRAS WT and KRAS mutant clones, and this finding correlates 
with tumour heterogeneity. Although peak height analysis is a relatively simple technique to determine 
quantitative allelic variations, it has been used before in a similar fashion [25,32]; This approach has been shown 
to be highly comparable to more laborious, expensive and time-consuming methodologies such as 
pyrosequencing and cloning-based sequencing [25]. Therefore, peak height analysis, in worst case scenario, 
may be a useable semi-quantitative method for evaluating allelic variation. Recent studies have also supported 
heterogeneity in GC with respect to established (HER2) and potential target genes [33]. Indeed, it stands as 
highly likely that, in the future, as more and more studies begin to unravel the field of tumoural heterogeneity, 
that this becomes a basic notion that influences patient stratification and treatment. 
If a KRAS mutation was to appear in the early stages of neoplastic development, it would make sense 
that the large majority of the cells harbour it, and this would in turn return a very high observed mutant-to-WT 
ratio. On the other hand, if mutations in KRAS occur as part of the tumour progression, this ratio would decrease. 
So, assuming that tumours have a tendency for heterogeneity, the tumour fragment taken for DNA extraction 
and mutation screening should be matched with a fragment that is submitted to histological analysis to increase 
the likelihood of obtaining reliable result on allelic fractions. To be more precise, the mutation analysis should 
even be done in material from the slide used for histological analysis and to determine the proportion of tumoural 
cells. In the present study, we used the first option to infer the heterogeneity in the sample, but we believe that 
future studies should follow the more meticulous approach described in the second option. 
In conclusion, the method for determining the full coding sequence of KRAS developed in this study 
stands as an easy, cost-effective and practical way to screen the entire coding sequence of the gene for 
mutations. The findings regarding mutation frequency suggest that KRAS mutation is frequent in MSI-positive 
GC cases, but if other mechanisms are also screened both in MSI and MSS cases, it is likely that the contribution 
of KRAS will increase in GC overall. Intratumoural heterogeneity and its practical consequences are still a 
clouded area, and advances in the assays used to determine the mutational status of tumours are bound to 
allow a deeper understanding of this feature. Also, our analysis for tumoural heterogeneity indicates that some 
MSI GC patients labelled as mutated for KRAS might bear the mutation in only a cellular clone and not the 
whole tumour. Further studies are needed to access the implications of this heterogeneity in therapy response. 
If new studies are designed to determine the efficacy of anti-EGFR therapy in GC, these should account for the 
differences at the molecular and genetic level between MSI and MSS cases, bearing in mind the high prevalence 
of KRAS mutated cases in the MSI group, the possibility for KRAS mutations in the MSS group, and the overall 
prevalence of KRAS amplification, with their accompanying anti-EGFR resistance. The mutational status in 
future studies should also consider using gene-wide assays for KRAS such as the one developed in this work, 
and perhaps for other RAS family members (e.g. NRAS), which have demonstrated to confer resistance to 
therapy with anti-EGFR molecules in CRC cases [16]. 
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Figure Legends 
 
Fig. 1 Determination of peak heights. a. A sample electropherogram is shown to illustrate how peak height 
measurements were made. H1 represents the height of the peak for the mutated nucleotide and H2 represents 
the height of the peak for the WT nucleotide. Below the electropherogram the formula used to calculate the 
allelic ratio is shown b. Three electropherograms used as controls and displaying an example of a common 
KRAS SNP found in the same cases. For this SNP, the height of each peak remains the same in each GC case, 
representing equivalent allelic fractions from both alleles 
 
Fig. 2 KRAS amplification strategy. A representative picture of agarose gel electrophoresis for each reaction is 
shown. On the right, an example of the obtained electropherograms is shown 
 
Fig. 3 Electropherogram and histological analysis of the mutated cases. In each part of the image, the upper 
left corner shows a 4x magnification light microscopy image of a slide of the tumour sample, reflecting the global 
aspect of the piece; the lower right corner shows a 20x magnification of a region in the same slide, demonstrating 
particular features for each case; the lower left corner shows the respective electropherogram and the 
corresponding mutation. a. case number 77. Upper left corner: image shows areas of tubular aspect (middle of 
the image), progressing to solid aspect and a region of fibrosis (upper right corner); Lower right corner: a few 
tubular structures are visible, along with the solid aspect (upper left corner) and a mild lymphoplasmocytic 
infiltrate. Tumoural cells make up at least 80% of the content. b. case number 88. Upper left corner: high cellular 
content is predictable, together with areas of fibrosis; Lower right corner: tubular structures are sparse and with 
low differentiation, and an abundant lymphoplasmocytic infiltrate is present, which accounts for the estimated 
percentage of tumoural cells of at least 60%. c. case number 95. Upper left corner: solid appearance with soft 
basophilic staining and areas of fibrosis; Lower right corner: solid tumour with adenosquamous differentiation. 
Tumoural cell percentage estimated to be at least 60%. d. case number 107. Upper left corner: some tubular-
like structures are visible together with fibrosis; Lower right corner: a mix of tubular and isolated cell patterns is 
observed, with a desmoplastic reaction. Tumoural cells should account for at least 80% of the cellular content. 
e. case number 181. Upper left corner: image filled with tubular appearing structures; Lower right corner: 
abundant tubular structures occupy the whole photograph. Tumoural cell percentage estimated to be of at least 
90% 
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Tables 
 
Table 1 Primer Identification, sequence and respective fragment size for each KRAS exon to be amplified. 
Primers used for Sanger sequencing are identified in bold. 
PRIMER IDENTIFICATION PRIMER SEQUENCE FRAGMENT SIZE 
EXON 2 
Forward 5’-AAAAGGTACTGGTGGAGTATTTGA 
293 bp 
Reverse 5’-TCATGAAAATGGTCAGAGAAACC 
EXON 3 
Forward 5’-TGCACTGTAATAATCCAGACTGTG 
296 bp 
Reverse 5’-TGGCATTAGCAAAGACTCAAAA 
EXON 4 
Forward 5’-AGTTGTGGACAGGTTTTGAAAGA 
351 bp 
Reverse 5’-ATGCCCTCTCAAGAGACAAAAA 
EXON 5 
Forward 5’-AAACTTCTTGCACATGGCTTTC 
275 bp 
Reverse 5’-GGTTGCCACCTTGTTACCTTTA 
EXON 6 
Forward 5’-TTCAGTTGCCTGAAGAGAAACA 
358 bp 
Reverse 5’-CTGCATGGAGCAGGAAAAA 
 
 
 
Table 2 Mutated cases and their mutated codon, nucleotide and the resulting mutation, expressed as the amino 
acid change. 
MUTATED
CASE 
MUTATED 
CODON 
NUCLEOTIDE 
ALTERATION 
TYPE OF 
MUTATION 
77 13 GGC to GAC G13D 
88 13 GGC to GAC G13D 
95 12 GGT to GAT G12D 
107 12 GGT to GAT G12D 
181 12 GGT to GTT G12V 
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Table 3 Mutated cases and respective percentage of tumoural cells, ratios and predicted heterogeneity. 
CASE 
% TUMOURAL CELLS 
(histological) 
EXPECTED MUT/WT 
ALLELIC KRAS RATIO 
OBSERVED MUT/WT 
ALLELIC KRAS RATIOa 
PREDICTED 
HETEROGENEITY 
77 ≥80% 67% 42% Yes 
88 ≥60% 43% 22% Yes 
95 ≥60% 43% 60% No 
107 ≥80% 67% 48% Yes 
181 ≥90% 82% 37% Yes 
aThis ratio was calculated based on the peak height of mutant and WT alleles for codons 12 and 13 of KRAS 
 
 
 
Supplementary Table 1 Map of mutations in KRAS coding sequence of the 19 MSI-positive cases. Mutated 
cases are depicted in red, with the respective aminoacid change. WT cases are represented in green. SNP 
are shown in yellow. 
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CASE NUMBER EXON 2 EXON 3 EXON 4 EXON 5 EXON 6 
63 WT WT WT WT rs1137282 
65 WT WT WT WT rs1137282 
74 WT WT WT WT WT 
77 G13D WT WT WT WT 
78 WT WT WT WT rs1137282 
86 WT WT WT WT WT 
88 G13D WT WT WT WT 
95 G12D WT WT WT WT 
96 WT WT WT WT WT 
103 WT WT WT WT WT 
107 G12D WT WT WT rs1137282 
114 WT WT WT WT WT 
119 WT WT WT WT WT 
157 WT WT WT WT WT 
175 WT WT WT WT rs1137282 
177 WT WT WT WT rs1137282 
181 G12V WT WT WT WT 
189 WT WT WT WT rs1137282 
191 WT WT WT WT WT 
Supplementary Table 1 
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